X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8820) 8820
Newsletter (1026) 1026
Publication (522) 522
Book Review (64) 64
Magazine Article (48) 48
Newspaper Article (32) 32
Book Chapter (17) 17
Dissertation (15) 15
Trade Publication Article (9) 9
Conference Proceeding (4) 4
Data Set (3) 3
Paper (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pravastatin (7474) 7474
humans (5774) 5774
male (4037) 4037
female (3351) 3351
middle aged (2808) 2808
aged (2187) 2187
statins (2187) 2187
cholesterol (2049) 2049
index medicus (2036) 2036
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (2015) 2015
simvastatin (2010) 2010
cardiac & cardiovascular systems (1796) 1796
pravastatin - therapeutic use (1788) 1788
pharmacology & pharmacy (1624) 1624
adult (1604) 1604
atorvastatin (1522) 1522
prevention (1454) 1454
animals (1383) 1383
anticholesteremic agents - therapeutic use (1330) 1330
hypercholesterolemia (1285) 1285
risk factors (1282) 1282
cholesterol, ldl - blood (1149) 1149
atherosclerosis (1142) 1142
hypercholesterolemia - drug therapy (1095) 1095
treatment outcome (1078) 1078
risk (1076) 1076
pravastatin - pharmacology (1034) 1034
coronary-heart-disease (1009) 1009
medicine, general & internal (993) 993
peripheral vascular disease (951) 951
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (941) 941
cholesterol - blood (917) 917
events (917) 917
research (907) 907
myocardial-infarction (906) 906
antilipemic agents (897) 897
men (825) 825
lovastatin (783) 783
atorvastatin calcium (712) 712
therapy (692) 692
coronary heart disease (687) 687
mortality (683) 683
disease (670) 670
rats (646) 646
drugs (637) 637
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (633) 633
drug therapy (618) 618
lipids (605) 605
heptanoic acids - therapeutic use (599) 599
double-blind method (597) 597
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (582) 582
cardiovascular agents (578) 578
pravastatin - administration & dosage (573) 573
analysis (567) 567
simvastatin - therapeutic use (546) 546
pyrroles - therapeutic use (544) 544
triglycerides - blood (533) 533
statin (526) 526
lipids - blood (513) 513
care and treatment (511) 511
prospective studies (505) 505
inflammation (504) 504
hypercholesterolemia - blood (503) 503
time factors (503) 503
c-reactive protein (501) 501
coronary disease - prevention & control (500) 500
cholesterol, hdl - blood (496) 496
follow-up studies (494) 494
dose-response relationship, drug (488) 488
coa reductase inhibitors (474) 474
heart-disease (473) 473
cardiovascular disease (472) 472
aged, 80 and over (466) 466
hyperlipidemias - drug therapy (453) 453
randomized controlled trials as topic (450) 450
rosuvastatin (450) 450
fluvastatin (442) 442
cardiovascular diseases - prevention & control (441) 441
low density lipoproteins (438) 438
efficacy (435) 435
cardiovascular-disease (431) 431
hypolipidemic agents - therapeutic use (430) 430
universities and colleges (427) 427
anticholesteremic agents - pharmacology (425) 425
reports (425) 425
medical research (413) 413
primary prevention (405) 405
mice (400) 400
coronary heart-disease (392) 392
cardiovascular diseases (390) 390
drug therapy, combination (387) 387
pravastatin - adverse effects (387) 387
safety (387) 387
health aspects (386) 386
hmg-coa reductase (370) 370
diabetes (367) 367
anticholesteremic agents - administration & dosage (361) 361
hydroxymethylglutaryl-coa reductase inhibitors (358) 358
hypertension (358) 358
medicine, experimental (358) 358
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9262) 9262
German (141) 141
Spanish (127) 127
French (102) 102
Japanese (98) 98
Russian (68) 68
Chinese (45) 45
Italian (38) 38
Portuguese (29) 29
Czech (8) 8
Korean (6) 6
Norwegian (6) 6
Swedish (6) 6
Polish (5) 5
Danish (4) 4
Dutch (4) 4
Serbian (3) 3
Hungarian (2) 2
Finnish (1) 1
Slovak (1) 1
Slovenian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Medicine, ISSN 1078-8956, 07/2008, Volume 14, Issue 7, pp. 767 - 772
Journal Article
Cell Biology International, ISSN 1065-6995, 05/2007, Volume 31, Issue 5, p. 451
Recent studies suggest that treatment with PPAR-[gamma] agonists and statins have beneficial effects on renal disease. However, the combined effects of... 
Pravastatin
Journal Article
American Journal of Obstetrics and Gynecology, ISSN 0002-9378, 2016, Volume 214, Issue 6, pp. 720.e1 - 720.e17
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2005, Volume 352, Issue 1, pp. 20 - 28
Statin therapy lowers not only low-density lipoprotein (LDL) cholesterol levels, but also levels of C-reactive protein (CRP), a marker of inflammation. This... 
MEDICINE, GENERAL & INTERNAL | DENSITY-LIPOPROTEIN CHOLESTEROL | INFLAMMATION | CARDIOVASCULAR-DISEASE | MARKERS | RISK | ACUTE CORONARY SYNDROMES | PRAVASTATIN | PRIMARY PREVENTION | PREDICTION | ATORVASTATIN | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Myocardial Infarction - blood | Heptanoic Acids - therapeutic use | Humans | Middle Aged | Male | Secondary Prevention | Coronary Disease - mortality | Incidence | C-Reactive Protein - metabolism | Pyrroles - administration & dosage | Heptanoic Acids - administration & dosage | Cholesterol, LDL - blood | Female | C-Reactive Protein - drug effects | Pyrroles - therapeutic use | Pravastatin - therapeutic use | Heptanoic Acids - pharmacology | Pravastatin - pharmacology | Coronary Disease - blood | Risk Factors | Proportional Hazards Models | Cholesterol, LDL - drug effects | Fluoroquinolones - therapeutic use | Biomarkers - blood | Atorvastatin Calcium | Coronary Disease - prevention & control | Pyrroles - pharmacology | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Myocardial Infarction - drug therapy | Pravastatin - administration & dosage | Anticholesteremic Agents - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Myocardial Infarction - prevention & control | Anticholesteremic Agents - pharmacology | Cardiovascular disease | Heart attacks | Cholesterol | Statins
Journal Article
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 10/2012, Volume 29, Issue 10, pp. 2860 - 2873
To develop physiologically based pharmacokinetic (PBPK) model to predict the pharmacokinetics and drug-drug interactions (DDI) of pravastatin, using the in... 
Biomedical Engineering | Biochemistry, general | Biomedicine | transporters | Pharmacy | physiologically based pharmacokinetic (PBPK) model | pravastatin | Medical Law | Pharmacology/Toxicology | drug-drug interaction | OATP1B1 | Drug-Drug interaction | Transporters | Physiologically based pharmacokinetic (PBPK) model | Pravastatin | COA REDUCTASE INHIBITORS | INTERINDIVIDUAL DIFFERENCES | HEALTHY-SUBJECTS | TRANSPLANT PATIENTS | HEPATIC-UPTAKE | CHEMISTRY, MULTIDISCIPLINARY | PHYSICOCHEMICAL PROPERTIES | CYCLOSPORINE-A | PHARMACOKINETICS | TISSUE DISTRIBUTION | IN-VIVO | PHARMACOLOGY & PHARMACY | Rifampin - pharmacokinetics | Area Under Curve | Humans | Middle Aged | Male | Hepatocytes - metabolism | Enzyme Inhibitors - administration & dosage | Young Adult | Drug Interactions | Biological Transport | Enzyme Inhibitors - pharmacokinetics | Computer Simulation | Cyclosporine - pharmacokinetics | Adult | Female | Rifampin - administration & dosage | Gemfibrozil - administration & dosage | Pravastatin - pharmacology | Organic Anion Transporters - antagonists & inhibitors | Liver - metabolism | Cells, Cultured | Gemfibrozil - pharmacokinetics | Pravastatin - administration & dosage | Adolescent | Cyclosporine - administration & dosage | Aged | Solute Carrier Organic Anion Transporter Family Member 1b1 | Pravastatin - pharmacokinetics | Pharmacology | Kinetics | Pharmaceutical sciences | Statins
Journal Article
International Journal of Pharmaceutics, ISSN 0378-5173, 12/2015, Volume 496, Issue 2, pp. 518 - 525
Wiechers’ programme “Formulating for Efficacy” initiated a new strategy to optimise the oil phase of topical formulations in order to achieve optimal... 
Transdermal delivery | Delivery gap theory | Pravastatin | Formulation | Wiechers | Franz cell | Pravastatin - administration & dosage | Administration, Cutaneous | Diffusion | Ointments | Chemistry, Pharmaceutical | Pravastatin - pharmacokinetics | Pravastatin - chemistry | PHARMACOLOGY & PHARMACY | SKIN | Transdermal medication | Antilipemic agents
Journal Article
Circulation, ISSN 0009-7322, 03/2016, Volume 133, Issue 11, pp. 1073 - 1080
Journal Article